Abstract
Breast cancer (BC) is a common cause of brain metastases occurring in at least 10–16 % of patients. Tucatinib is FDA-approved for patients with metastatic HER2-positive BC, including patients with brain metastases, whereas no approved targeted therapies are available for HER2-negative brain metastasis. This study aims to elucidate the expression patterns of HER2 and HER3 in primary tumors and brain metastases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
